Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsFRA:S0N0 -2.05%19 Return-on-Tangible-Equity is -45.17% as of Apr. 2026. GuruFocus rates FRA:S0N0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,197 Biotechnology companies, enGene Therapeutics ranks worse than 57.81% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. enGene Therapeutics's annualized net income for the quarter that ended in Apr. 2026 was €-103.38 Mil. enGene Therapeutics's average shareholder tangible equity for the quarter that ended in Apr. 2026 was €228.88 Mil. Therefore, enGene Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Apr. 2026 was -45.17%.
The historical rank and industry rank for enGene Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
FRA:S0N0'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -407.91 Med: -53.28 Max: -31.96
Current: -56.01
During the past 6 years, enGene Therapeutics's highest Return-on-Tangible-Equity was -31.96%. The lowest was -407.91%. And the median was -53.28%.
FRA:S0N0's Return-on-Tangible-Equity is ranked worse than 57.81% of 1197
companies
in the Biotechnology industry
Industry Median: -42.85
vs FRA:S0N0: -56.01
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
enGene Therapeutics Return-on-Tangible-Equity Related Terms
enGene Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S0N0 vs VTVT, GUTS, VXRT: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, enGene Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -45.17% mean?
enGene Therapeutics (FRA:S0N0) has a Return-on-Tangible-Equity of -45.17% as of Apr. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on enGene Therapeutics and its competitors. According to the industry distribution chart, enGene Therapeutics ranks #692 out of 1197 companies in the Biotechnology industry, placing it in the top 57.8%.
Is enGene Therapeutics' Return-on-Tangible-Equity too high?
enGene Therapeutics' current Return-on-Tangible-Equity is -45.17%. Based on the distribution chart, enGene Therapeutics ranks #692 out of 1197 companies in the Biotechnology industry, which is below the industry midpoint. Overall, enGene Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Return-on-Tangible-Equity compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #692 out of 1197 companies for Return-on-Tangible-Equity. This places enGene Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current Return-on-Tangible-Equity is -45.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (FRA:S0N0) has a current Return-on-Tangible-Equity of -45.17%. The current Return-on-Tangible-Equity is -45.17%. enGene Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For enGene Therapeutics (FRA:S0N0), the current Return-on-Tangible-Equity is -45.17% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
19GF Score
Get the complete analysis for FRA:S0N0
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S0N0 has been successfully added to your 
